Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors

Breast Cancer Research and Treatment
Gitana AcetoRenato Mariani-Costantini

Abstract

The role of non-genetic factors as modifiers of TP53-related hereditary breast cancer (BC) risk is debated. In this regard, little is known about the impact of germline TP53 mutations on BC in sub-Saharan Africa, where the disease often presents in non-contraceptive multiparous premenopausal women with extended history of breastfeeding. Herein, we report the germline TP53 mutations found in a series of 92 Sudanese premenopausal BC patients characterized for reproductive history. The entire TP53 coding sequence, including intron-exon boundaries and UTRs, was analyzed via DHPLC and direct sequencing, and the association of TP53 genotypes with BC risk and with individual lifetime exposures to reproductive factors was investigated with statistical tools. The germline TP53 mutation spectrum comprised 20 variants, 15 in the non-coding and 5 in the coding region. The latter included a deleterious missense mutation, c.817C>T (p.Arg273Cys), in a unique patient, and the common and functionally relevant coding polymorphism at amino acid 72 [Pro72Arg (rs1042522)]. The non-coding mutations included c.919+1G>A, a known deleterious splice site mutation, also in a unique patient. Notably, the 2 carriers of deleterious TP53 mutations clustered ...Continue Reading

References

May 1, 1991·CA: a Cancer Journal for Clinicians·J L Kelsey, M D Gammon
Feb 5, 2003·Nature Genetics·Patrick DumontMaureen Murphy
Aug 3, 2004·Nature Genetics·A John IafrateCharles Lee
Mar 1, 2005·Experimental Gerontology·Diana van HeemstUNKNOWN Long Life study group
Apr 29, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fiona LallooD Gareth R Evans
Mar 3, 2007·Breast Cancer Research and Treatment·Khalid Dafaallah AwadelkarimRenato Mariani-Costantini
Jun 1, 2007·Breast Cancer Research : BCR·Tatsuya ToyamaYoshitaka Fujii
Jan 24, 2009·Nature Reviews. Cancer·Catherine WhibleyMonica Hollstein
Dec 19, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Byeong-Seon JeongArnold J Levine
Sep 3, 2010·Nature·UNKNOWN International HapMap 3 ConsortiumJean E McEwen
Oct 12, 2012·Molecular Biology Reports·Huda A EltahirMuntaser E Ibrahim
Mar 13, 2013·Nature Reviews. Clinical Oncology·Renato Mariani-Costantini
Apr 15, 2014·Familial Cancer·Ida BiunnoRenato Mariani-Costantini
Jan 7, 2016·Frontiers in Oncology·James S LawsonNoel J Whitaker
Nov 20, 2016·The Lancet Global Health·Elima Jedy-AgbaIsabel Dos-Santos-Silva
Feb 22, 2018·Genes & Development·Subhasree BasuMaureen E Murphy
Sep 29, 2018·Global Health, Epidemiology and Genomics·A AbbadF Radouani

❮ Previous
Next ❯

Citations

Mar 5, 2021·Frontiers in Oncology·Solomon O RotimiBodour Salhia

❮ Previous
Next ❯

Software Mentioned

SPSS Advanced Statistics
Wave ® Nucleic Acid Fragment Analysis System

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.